<DOC>
	<DOC>NCT02437981</DOC>
	<brief_summary>PrEP-30 is a demonstration project to assess the feasibility of providing oral PrEP to MSM and other individuals at-risk for HIV in Bangkok, Thailand as a service that is funded entirely through user fees. Tenofovir disoproxil fumarate/emtricitabine PrEP is provided part of a combined HIV prevention program that includes risk-reduction counseling, regular HIV testing, and the provision of condoms and lubricants. PrEP-30 is implemented at the Thai Red Cross AIDS Research Centre, at the site of the largest HIV counseling and testing center in Thailand.</brief_summary>
	<brief_title>Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic</brief_title>
	<detailed_description />
	<criteria>1. Age &gt; 18 years 2. HIV test negative 3. Creatinine clearance &gt; 60 ml/min 4. No contraindication or allergy to PrEP medications (TDF/FTC) 5. At least one risk factor for HIV infection within the previous 6 months: sex partner known to be HIV positive works as commercial sex worker use of PEP for sexual exposure injection drug use any STI (syphilis, gonorrhea, chlamydia) &gt; 5 sex partners inconsistent condom use with highrisk partners, including MSM, IDU MSM: any insertive or receptive anal sex without condom Women: any sex without condom with highrisk male partner (MSM, IDU, multiple female partners) Heterosexual men: any sex without condom with highrisk female partner (commercial sex worker, IDU, multiple male partners)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>